Unknown

Dataset Information

Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms.


ABSTRACT:

Introduction

Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin receptor expressing neuroendocrine neoplasms has shown promising results in clinical trials and a recently published phase III study.

Methods

In our center, 2294 patients were screened between 2004 and 2014 by 68Ga somatostatin receptor (SSTR) PET/CT. Intention to treat analysis included 1048 patients, who received at least one cycle of 90Yttrium or 177Lutetium-based PRRT. Progression free survival was determined by 68Ga SSTR-PET/CT and EORTC response criteria. Adverse events were determined by CTCAE criteria.

Results

Overall survival (95% confidence interval) of all patients was 51 months (47.0-54.9) and differed significantly according

SUBMITTER: Baum RP 

PROVIDER: S-EPMC5908296 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature